Upregulation of the MDR1 (multidrug resistance 1) gene is involved in the development of resistance to antifungal agents in clinical isolates of the pathogen Candida albicans. To better understand the molecular mechanisms underlying the phenomenon, the cis-acting regulatory elements present in the MDR1 promoter were characterized using a b-galactosidase reporter system. In an azole-susceptible strain, transcription of this reporter is transiently upregulated in response to either benomyl or H 2 O 2 , whereas its expression is constitutively high in an azoleresistant strain (FR2). Two cis-acting regulatory elements within the MDR1 promoter were identified that are necessary and sufficient to confer the same transcriptional responses on a heterologous promoter (CDR2). One, a benomyl response element (BRE), is situated at position "296 to "260 with respect to the ATG start codon. It is required for benomyl-dependent MDR1 upregulation and is also necessary for constitutive high expression of MDR1. A second element, termed H 2 O 2 response element (HRE), is situated at position "561 to "520. The HRE is required for H 2 O 2 -dependent MDR1 upregulation, but dispensable for constitutive high expression. Two potential binding sites (TTAG/CTAA) for the bZip transcription factor Cap1p (Candida AP-1 protein) lie within the HRE. Moreover, inactivation of CAP1 abolished the transient response to H 2 O 2 . Cap1p, which has been previously implicated in cellular responses to oxidative stress, may thus play a trans-acting and positive regulatory role in the H 2 O 2 -dependent transcription of MDR1. A minimal BRE ("290 to "273) that is sufficient to detect in vitro sequence-specific binding of protein complexes in crude extracts prepared from C. albicans was also defined. Interestingly, the sequence includes a perfect match to the consensus binding sequence of Mcm1p, raising the possibility that MDR1 may be a direct target of this MADS box transcriptional activator. In conclusion, while the identity of the trans-acting factors that bind to the BRE and HRE remains to be confirmed, the tools developed during this characterization of the cis-acting elements of the MDR1 promoter should now serve to elucidate the nature of the components that modulate its activity.
INTRODUCTION
The yeast Candida albicans is an opportunistic pathogen that causes oral, vaginal or systemic infections in immunocompromised individuals and immunocompetent women (Coleman et al., 1993) . The azole class of antifungals (for example fluconazole) is widely used to treat C. albicans infections. Fluconazole-resistant strains have emerged, especially in HIV-positive patients with recurrent candidiasis who have undergone prolonged fluconazole therapy (Ghannoum et al., 1996; Law et al., 1994; Marr et al., 2000; Rex et al., 1995) . The molecular mechanisms proposed to explain azole resistance are diverse: (i) the cellular content of the azole target Erg11p (ergosterol biosynthesis), a 14a-lanosterol demethylase, can be elevated, (ii) the affinity of Erg11p for azole antifungal agents can be decreased, (iii) the ergosterol biosynthetic pathway can be altered by inactivation of the sterol D 5,6 -desaturase and (iv) cells can fail to accumulate these agents due to the upregulation of multidrug transporters belonging to the ABC transporters and the major facilitator (MF) families. Some azole-resistant strains upregulate the ABC transporters CDR1 (Candida drug resistance) and CDR2, while others upregulate MF MDR1 (multidrug resistance 1) (Sanglard & Odds, 2002; White et al., 1998) .
Overexpression and gene inactivation studies have shown that MDR1 confers specific resistance to fluconazole, benomyl, cycloheximide, benzotriazole, methotrexate, 4-nitroquinoline-N-oxide (4-NQO) and sulfomethuron methyl (Ben-Yaacov et al., 1994; Fling et al., 1991; Goldway et al., 1995; Wirsching et al., 2000b) . Disruption of MDR1 causes an increased susceptibility to methotrexate, cycloheximide and 4-NQO (Goldway et al., 1995; Sanglard et al., 1996) . However, its inactivation does not increase susceptibility to benomyl, suggesting that other mechanisms are involved in this resistance (Goldway et al., 1995) . MDR1 is usually not expressed at detectable levels in fluconazole-susceptible C. albicans isolates but its constitutive upregulation in some fluconazole-resistant isolates reveals a correlation between azole resistance and overexpression of MDR1 (Franz et al., 1998; Sanglard et al., 1995; White, 1997; White et al., 1997) .
Little is known about the transcriptional regulation of MDR1 in C. albicans. However, a dramatic transient upregulation of MDR1 can be observed in azole-susceptible strains after treatment with toxic hydrophobic agents (benomyl, methotrexate, 4-NQO, o-phenanthroline), oxidizing agents [diamide, H 2 O 2 , tert-butyl hydrogen peroxide (T-BHP) and diethylmaleate] and the alkylating agent methyl methanesulfonate (Gupta et al., 1998; Harry et al., 2005) . Clinical isolates with increased MDR1 expression have not undergone amplification of the MDR1 gene (Wirsching et al., 2000a) . Sequence analysis of MDR1 promoters from clinical isolates compared to wild-type promoters did not reveal cis-acting mutations (Harry et al., 2005; Wirsching et al., 2000a) . Thus MDR1 upregulation in clinical strains is most likely due to transcriptional activation resulting from mutations of factors acting in trans (Wirsching et al., 2000a) . Deletion analysis of the MDR1 promoter, performed with a luciferase reporter gene, suggested that regulatory functions could be assigned to two separate regions: an element required for induction by benomyl was assigned to the region between 2399 and 2299 upstream of the start codon and another region located between 2601 and 2500 was responsible for MDR1 induction by the oxidative agent T-BHP.
In Saccharomyces cerevisiae, drug resistance is also mediated by membrane transport proteins belonging to the ABC transporter and major facilitator superfamilies and the different mechanisms controlling the expression of these multidrug resistant genes are relatively well understood (SaCorreia & Tenreiro, 2002; Taglicht & Michaelis, 1998) . The homologue of MDR1, FLR1, confers resistance to multiple drugs such as fluconazole, 4-NQO, cycloheximide, methotrexate and benomyl (Alarco et al., 1997; Broco et al., 1999; Nguyen et al., 2001; Tenreiro et al., 2001) . Induction of FLR1 expression by the oxidizing agents H 2 O 2 , diamide, T-BHP and diethylmaleate, as well by the alkylating agent methyl methanesulfonate (Broco et al., 1999; Jelinsky & Samson, 1999; Nguyen et al., 2001) , is mediated by Yap1p (also called Pdr4p or Snq3p), a basic leucine zipper (bZip) transcription factor (Nguyen et al., 2001; Tenreiro et al., 2001) . The direct targets of Yap1p, principally genes involved in oxidative stress, have a common promoter element, the palindromic YRE (Yap1p response element: TTAC/GTAA) (Fernandes et al., 1997; Kuge & Jones, 1994; Toone & Jones, 1999 ).
In C. albicans, Cap1p, a bZip transcription factor structurally and functionally related to S. cerevisiae Yap1p, has been implicated in multidrug resistance and oxidative stress resistance (Alarco & Raymond, 1999; Wang et al., 2006; Zhang et al., 2000) . It was also shown to confer fluconazole resistance in S. cerevisiae by transcriptionally activating FLR1 (Alarco et al., 1997) , suggesting it has the same sequence specificity as Yap1p. Conversely, the C. albicans MDR1 promoter harbours the putative Cap1p-binding site (TTAGTAA at 2532). Together these data indicate that mechanisms regulating MDR1 and its S. cerevisiae orthologue may be grossly similar. However, while in S. cerevisiae inactivation of Yap1p abolished FLR1 transcription (Tenreiro et al., 2001) , Alarco & Raymond (1999) showed that disruption of CAP1 in the azole-resistant strain FR2 did not suppress but rather increased the level of MDR1 expression. In C. albicans Cap1p may act as both a repressor and an activator of MDR1 transcription, since experiments performed by Harry et al. (2005) demonstrating the importance of the YRE in the T-BHP response suggest that Cap1p is an activator of MDR1 expression in response to oxidative stress.
In this study, we used a reporter system to explore the transcriptional regulation of MDR1 in azole-resistant and azole-susceptible strains. The system has identified two different cis-acting regulatory elements and has permitted us to locate them at high resolution. The first, located between 2296 and 2260, was responsible for dramatic MDR1 upregulation in an azole-susceptible strain exposed to benomyl as well as for high constitutive expression in an azole-resistant strain. The second, which harbours two putative binding sites for Cap1p, is located between 2561 and 2520. Like the trans-acting Cap1p, this cis-acting element was not required for high constitutive expression of MDR1 in an azole-resistant strain. However, the response of MDR1 to H 2 O 2 was dependent upon the presence of both Cap1p and its binding site within the MDR1 promoter. The benomyl-dependent response was also partially dependent upon the presence of Cap1p, raising the possibility that interactions may occur between complexes bound at the two regulatory elements.
METHODS
Strains and media. The C. albicans strains used in this study are listed in Tables 1 and 2 . Strains were grown either in complete medium YEPD [1 % Bacto peptone (Difco), 0?5 % yeast extract (Difco) and 2 % glucose (Fluka)] or in minimal medium YNB [Yeast Nitrogen Base (Difco) and 2 % glucose (Fluka)]. For solid media, 2 % agar (Difco) was added to both media. Escherichia coli DH5a (Hanahan, 1985) was used as a host for plasmid construction and propagation. DH5a was grown in Luria-Bertani (LB) broth or LB agar plates supplemented with ampicillin (0?1 mg ml 21 ) when required.
Yeast transformation. Cells from 0?2 ml of a stationary-phase culture were resuspended in 0?1 ml of a solution containing 200 mM lithium acetate pH 7?5, 40 % (w/v) polyethylene glycol 8000, 15 mg DTT ml 21 and 250 mg denatured salmon sperm DNA ml 21 . Linearized transforming DNA (0?5-4 mg) was added to the yeast suspension, which was incubated at 44 uC for 60 min. Transformation mixtures were plated directly onto selective medium and incubated for 2-3 days at 30 uC.
Construction of promoter-lacZ fusions. To generate MDR1-lacZ and CDR2-lacZ fusions used in drug-induction assays, the 999 bp MDR1 and 903 bp CDR2 promoters were first amplified by PCR using the Taq DNA polymerase (Roche), with primers MDR1-59-999-KPN and MDR1-39-PST or primers CDR2-KPN and CDR2-PST (Table 3 ). The generated fragments were cloned into pAU36 (Uhl & Johnson, 2001 ) previously digested with KpnI and PstI. The resulting plasmids (pBR1 and pDS295, respectively) were digested with either NruI for the MDR1-lacZ fusion or SnaBI for the CDR2-lacZ fusion prior to transformation into C. albicans, resulting in their integration at the MDR1 and CDR2 loci, respectively.
For analysis of MDR1 promoter deletions, a cassette containing the 59 and 39 flanking regions of MDR1 was inserted into the BamHI site of pAU36. This cassette was designed to contain a restriction site (NheI) to separate the 59 and 39 flanking regions of MDR1, therefore allowing linearization of promoter-lacZ fusions in pAU36-derived plasmids and integration at the MDR1 genomic site (see also Fig. 1a) . The cassette was prepared in a two-step process. C. albicans genomic DNA was used as a PCR template to amplify two distinct 500 bp fragments that overlap by the presence of the NheI restriction site. In this step, the external primers UTR3-59 and UTR5-39 were used with internal primers UTR3-39bis and UTR5-59bis (Table 3) with the Expand High Fidelity system (Roche). The two purified PCR fragments were then used as a PCR template with external primers (UTR3-59 and UTR5-39). The resulting product was next introduced into the BamHI site of pAU36 to generate pBR4. The 59 deletions of the promoter region were generated by PCR using the reverse primer MDR1-39-PST and the different forward primers listed in Table 3 . The resulting fragments were inserted at the KpnI and PstI sites of pBR4 to generate the plasmids listed in Table 3 . For the construction of internal deletions and transversions within the MDR1 promoter, a similar two-step PCR strategy was used. First, external primers MDR1-59-598-KPN and MDR1-39-PST were used with variable primers designed for specific deletions and transversions to generate fragment pairs with a 20 bp overlap region (Table 4) . After purification, the overlapping fragment pairs were used as templates with external primers to reconstitute MDR1 promoter derivatives. The fragments obtained were cloned into the KpnI and PstI sites of pBR4 to generate the plasmids listed in Table 4 . All plasmids generated were linearized by NheI and their correct integration as a single copy at the MDR1 locus was verified by Southern blotting (see also Fig. 1b) .
Renilla luciferase reporter system. Chimeric CDR2 promoters containing the BRE (50 bp, 2309 to 2260) or the HRE (41 bp, 2556 to 2516) fused to the Renilla luciferase (RLUC) reporter system were constructed by the following procedures. The plasmid pAC66, containing the HIS3 ORF under the control of the BRE (50 bp) CDR2 promoter (198 bp) (D. Sanglard, unpublished) , was used as a template for PCR with primer LUCCDR23 and BRE50F-CDR2-X or YRE50FCDR2p-XBA. The primer BRE50F-CDR2-X adds an XbaI restriction site to the 59 end of the BRE whereas the primer YRE50FCDR2p-XBA overlaps with the 59 end of CDR2 promoter and contains 41 bp of the HRE. The constant primer LUCCDR23 overlaps the 39 end of the CDR2 promoter and adds a PstI restriction site at the 39 end of the BRE-or HRE-fused CDR2 promoter (see Table 5 ). The resulting PCR fragments were digested with XbaI and PstI, then inserted into compatible sites of pMM43 to generate pBR101 and pBR108. The plasmid pMM43 (de Micheli et al., 2002) contains the RLUC reporter system and 198 bp of the CDR2 promoter but lacks the drug-responsive element (DRE), an element required for CDR2 upregulation. This plasmid was used as a negative control in luciferase reporter assays. As a positive control, the promoter of MDR1, 598 bp, was first amplified by PCR from plasmid pBR6 using primers MDR1-59-598-KPN and MDR1-39-PST. Digestion of the PCR product by XbaI and PstI generated a fragment of 592bp (2592 to +1) due to the presence of a XbaI restriction site at position 2592 of the promoter. This fragment was inserted into the compatible sites of pMM43 to obtain pBR99.
To insert additional BRE or HRE, complementary primers (X-BRE50F-X and X-BRE50R-X for the BRE, and Xba-YRE.F-XBA and Xba-YRE.R-XBA for the HRE) with XbaI site extensions were annealed by progressive diminution of temperature from 95 uC to room temperature. Annealed fragments were phosphorylated with T4 polynucleotide kinase (Roche) and placed upstream of the BRE CDR2 promoter cloned in pRB101 previously digested by XbaI. All plasmids containing the RLUC reporter system were inserted at the C. albicans LEU2 genomic locus after digestion by SalI, which cuts at a single site in the LEU2 gene in these plasmids.
DNA amplification by PCR. DNA fragments used in cloning steps or as probes were generated by PCR with the Taq DNA polymerase (Roche) following the instructions of the manufacturer. The reaction DPrimers from pBR7 to pBR37 were used in combination with the reverse primer MDR1-39-PST. dThe amplified region corresponds to the terminator of MDR1.
mixture (final volume 100 ml) was composed of 10 ml of 106 Taq DNA polymerase buffer (Roche), 10 ml of MgCl 2 (Roche), 1 ml of each 100 mM forward and reverse primer, 4 ml of 10 mM deoxynucleoside triphosphates (Roche), 10 U of Taq DNA polymerase and 1 ml of 0?5-1 mg ml 21 genomic DNA. PCR was performed under the following conditions: one cycle for 4 min at 94 uC, 1 min at 54-60 uC and 2 min at 72 uC; 30 cycles for 30 at 94 uC, 1 min at 54-60 uC and 2 min at 72 uC followed by one terminal cycle for 10 min at 72 uC. After analysis of 1/10 vol. of PCR products by electrophoresis on 1 % agarose gel, DNA fragments were purified with the QIAquick PCR purification kit (QIAGEN) and resuspended in 50 ml sterile water.
Southern blotting. Southern blots were carried out as described previously (Sanglard et al., 1999) . DNA probes used in this study were generated by PCR using the following pairs of primers: for the verification of genomic insertion of pMM43-derived plasmids at the LEU2 genomic locus, CALEU2-3 (59-CACCACCACTAAAACCC-CAACAAATCA-39) and CALEU2-5 (59-ATGTCTGTTAAAACCCA-AACCATTACT-39); for insertion of pAU36-derived plasmids at the MDR1 locus, MDR1-59-501-KPN (59-GCGCAAAGGTACCCAAT-TTTCATTTTAGGAAATTTACCGAGTTT-39) and LacZ-rev (59-ATGTCTGTTAAAACCCAAACCATTACT-39). Radioactive DNA probes were generated by random priming using the Megaprime DNA labelling kit (Amersham). Radioactive signals were revealed by exposure to Kodak BioMax MR film (Amersham Biosciences).
Electrophoretic mobility shift assays (EMSAs). Protein extracts from C. albicans strain CAF2-1 were prepared from 2 l cultures in YEPD grown to mid exponential phase until the density reached 1?5610 7 cells ml
21
. An equal quantity of cells was exposed to benomyl (35 mg ml 21 ) for 30 min or left untreated as a control. The benomyl-treated or control cells were centrifuged for 20 min at 5500 r.p.m. and each cell pellet was washed with 10 ml extraction buffer [400 mM (NH 4 ) 2 SO 4 , 10 mM MgCl 2 , 1 mM EDTA, 10 % (v/v), glycerol, 7 mM mercaptoethanol, 200 mM Tris/HCl pH 8]. Washed cells were centrifuged for 10 min at 5500 r.p.m. and the pellet obtained was resuspended in 10 ml extraction buffer supplemented with a protease inhibitor mix (Roche). Glass beads (10 g) Fig. 1 . Insertion of MDR1-lacZ fusions at the C. albicans MDR1 genomic locus. (a) Schematic representation of MDR1-lacZ fusions at the genomic MDR1 locus. The plasmids containing the MDR1 promoters (P) fused to lacZ were first digested with NheI and were integrated by double crossing over at the MDR1 genomic locus using sequences (UTR59 and UTR39) flanking MDR1 inserted at the BamHI restriction site of pAU36. Restriction maps of the MDR1 genomic locus are shown with and without insertion of the MDR1-lacZ fusion constructs. (b) Southern blot analysis of genomic DNA from strains derived from FR2 and transformed with different lengths of promoter. Genomic DNA was digested with NsiI and transferred onto a GeneScreen Plus nylon membrane. Hybridization of the restricted genomic DNA with the MDR1 labelled probe [represented in (a) by a black bar] yielded one fragment of 2?7 kb for the wild type strain and an additional fragment, of between 6?1 and 7?3 kb, for the yeast transformants, depending of the length of the inserted promoter. A double insertion of the plasmid into the C. albicans genome yielded an additional signal at approximately 8?4-9?7 kb.
were added to the cell suspension and the resulting mixture was disrupted for 5 min at 4 uC using a Macro bead-beater (Biospec Products). The homogenized solution was kept on ice for 30 min before centrifugation at 4 uC for 30 min at 13 000 r.p.m. The supernatant was transferred to a new tube and the cell pellet was reextracted with 5 ml fresh extraction buffer. The two supernatants were combined and the resulting solution was centrifuged for 1 h at 13 000 r.p.m. at 4 uC. The supernatant was recovered and ammonium sulfate was added to a final concentration of 0?3 g ml 21 . After dissolution of ammonium sulfate, the protein extract was centrifuged for 10 min at 13 000 r.p.m. and 4 uC. Precipitated proteins were resuspended in 250 ml protein buffer (20 mM HEPES, 5 mM EDTA, 7 mM mercaptoethanol, 1 mM PMSF and 20 % glycerol) supplemented with protease inhibitors (Roche). Protein concentrations of the crude extracts were determined using the Bradford method.
Double-stranded oligonucleotide probes were prepared by annealing 59 end labelled oligonucleotides with their complementary strands. The sequences of the probes are described in Figs 7 and 8. Single-strand oligonucleotides (5 pmol) were incubated at 37 uC for 45 min with 10 U T4 polynucleotide kinase (Roche) and 40 mCi (1?48 MBq) [c- P] ATP was eliminated using the Nucleotide Removal kit (Qiagen). The last elution step was performed with 100 ml of sterile water. After addition of the unlabelled oligonucleotides, the annealing of the complementary strands was performed by progressive temperature reduction after a 3 min treatment at 95 uC.
EMSA was carried out with 30 mg protein extract to which was added 7 ml binding buffer [20 mM HEPES pH 7?9, 50 mM KCl, 0?5 mM EDTA (Invitrogen), 0?1 % Nonidet P-40, 1 mg bovine serum albumin (Sigma) ml 21 and 5 % glycerol (Invitrogen)], 1 ml poly[d(I-C)] (Roche) (1 mg ml 21 ), 1 ml 0?2 M PMSF, 1 ml 0?1 M DTT and 10 fmol labelled probe (approx. 10 6 c.p.m.). The mix was incubated at room temperature for 20 min. In competition experiments, 250-, 500-and 1000-fold excess of unlabelled double-stranded oligonucleotides, corresponding to a promoter region of the RTA4 gene, were added just before the labelled probes. After addition of 3 ml 40 % glycerol, the reactions were loaded onto a non-denaturing 5 % polyacrylamide gel containing 0?56 Tris/borate/EDTA. In parallel, 20 ml loading buffer for proteins was loaded to follow probe migration. Gels were run at 150 V in 0?56 TBE buffer, then transferred to Whatman 3 MM paper and dried under vacuum. Probes were detected by autoradiography.
Measurement of b-galactosidase reporter activities. Cells were grown overnight in 3 ml YEPD at 30 uC under constant agitation. Cultures were then diluted in 5 ml fresh medium to obtain a . At this point, 1 ml aliquots from cultures that were not exposed to drugs (azole-resistant strains FR2 or MMY412) were centrifuged at 4 uC for 5 min at 5500 r.p.m. Exposure of other strains (azole-susceptible strains DSY449 and MMY411) to different drugs was carried out for defined time periods at 30 uC with constant agitation. After drug exposure, cell density was measured and cultures were centrifuged at 4 uC and 5500 r.p.m. for 10 min. The cell pellets were washed with 1 vol. Z buffer (60 mM Na 2 HPO 4 , 40 mM NaH 2 PO 4 , 10 mM KCl, 1 mM MgSO 4 ) and centrifuged at 4 uC for a further 10 min. The washed cell pellets were resuspended in 150 ml Z buffer supplemented with 38?6 mM mercaptoethanol. After addition of 50 ml chloroform and 20 ml 0?1 % SDS, cells were disrupted by vortexing. To each aliquot was added 700 ml ONPG (1 mg ml 21 ; Sigma) in Z buffer supplemented with mercaptoethanol and preheated at 30 uC. The mixtures were incubated at 37 uC until they developed a yellow colour (20 min to 3 h). The enzyme was inactivated by the addition of 500 ml 1 M Na 2 CO 3 . The mixtures were centrifuged at 13 000 r.p.m. for 10 min and the OD 420 was read. The b-galactosidase activities were calculated using the following equation: b-galactosidase activity (Miller units)=(10006OD 420 )/ (t6v6OD 600 ), where t is the time of reaction expressed in min and v is the volume of culture used in the assay expressed in ml.
Measurement of Renilla luciferase reporter activities. Cells were grown overnight in 3 ml YEPD at 30 uC under constant shaking, then diluted in 5 ml fresh medium to obtain a cell density of approximately 1?5610 7 cells ml
. Benomyl (35 mg ml
) was added to the cell suspensions and cultures were incubated with constant shaking at 30 uC for a further 30 min. After drug exposure, cells were centrifuged for 10 min at 5500 r.p.m. The pellet was washed twice with 1 ml cold sterile water followed by 1 ml cold RLUC buffer (0?5 M NaCl, 0?1 M K 2 HPO 4 , 1 mM EDTA, 0?6 mM sodium azide). The final pellet was resuspended in 200 ml cold RLUC buffer supplemented with protease inhibitors (Roche) and an equal volume of chilled acid-washed glass beads was added. The cells were disrupted at 4 uC for 30 s using a Minibead beater (Biospec Products) and then centrifuged at 4 uC for 10 min at 13 000 r.p.m. The supernatants containing soluble proteins were stored at 220 uC or used directly for measurement of luciferase activities.
The relative luciferase activities of the different clones were measured using the Dual-Luciferase kit (Promega). Five microlitres of the crude protein extracts was added to 25 ml LAR II buffer according to the recommendations of the manufacturer and firefly luciferase activities were measured using a Lumat LB 9507 luminometer (E. G. and G. Berthold). Twenty-five microlitres of freshly prepared STOP and GLO buffer was then added to the reactions and Renilla luciferase activities were measured. Specific luciferase activities, expressed in Renilla luciferase units [RLU; i.e. U (mg protein) 21 ] were calculated after determination of the protein concentration of cell extracts by the Bradford method.
Statistical analysis. For the analysis of promoter deletions, a mathematical model was fitted using non-linear least squares. The choice of the model was based on the observation that, starting from a maximal response (H 1 in the equation), the response decreases to a minimum level (H 0 ) over a very short interval of length. The centre of this interval (A) represents the critical length for loss of response, while the width of this interval indicates the abruptness of the change (the slope B). The final equation was y=H 0 +(H 1 2H 0 )/{1+exp[(A2x)/B]}, where y is the response and x the promoter length. For the mutant strains (cap1D/D), the same equation was used with parameters written in lower case (h 0 , h 1 , a, b). The fit of these equations contained eight parameters. The differences between the parameters determined for the wild type strain and the corresponding mutant were next tested using the generalized F test.
Comparisons between two sets of values (e.g. promoter bearing transversion or deletion versus wild type promoter) were performed using the nonparametric Mann-Whitney test.
RESULTS
The upregulation of MDR1 occurring in clinical azole-resistant strains is mimicked by exposure to benomyl, H 2 O 2 and diamide To analyse the transcriptional activity of MDR1, the proximal 999 bp of the MDR1 promoter was fused in (Uhl & Johnson, 2001 ). The promoter fusion (MDR1-lacZ) was integrated in the azole-susceptible mutant strain DSY449 (cdr1D/D) at the MDR1 locus as described in Methods. We chose to use this strain because the absence of CDR1 may reduce drug efflux and thereby enhance the sensitivity of drug-dependent MDR1 activation.
Upregulation of MDR1 can occur in C. albicans azoleresistant strains or in azole-susceptible strains exposed to diverse drugs including benomyl and H 2 O 2 (Gupta et al., 1998; Harry et al., 2005) . Therefore we tested the response of the reporter to a panel of compounds known as inducers of MDR1. In order to test the MDR1 response specificity, we also tested the response to oestradiol and fluphenazine, compounds known to induce CDR2 (de Micheli et al., 2002) . For this purpose, a CDR2-lacZ reporter system was integrated in DSY449 in the same fashion as for the MDR1-lacZ construct. The relative increase of MDR1-lacZ and CDR2-lacZ reporter activities after treatment of C. albicans with these compounds is shown in Table 6 . Upon exposure to benomyl, H 2 O 2 or diamide, MDR1-lacZ reporter activities increased more than 10-fold as compared to untreated conditions, while no increase was observed for the CDR2-lacZ promoter fusion. In contrast, oestradiol and fluphenazine treatment specifically increased CDR2-lacZ reporter activities (by approximately 100-fold). Thus, the response of the two reporter genes to five different agents phenocopies the effects on the endogenous MDR1 and CDR2 genes. Exposure of C. albicans to methotrexate, sulfomethuron methyl and phenanthroline had no influence on transcription of either reporter. Based on these results, responses to the hydrophobic compound benomyl and to the oxidizing agent H 2 O 2 were selected as readouts for the functional dissection of the MDR1 promoter. As the chemical properties of these drugs are different, we reasoned that they might reveal different modes of activation of the MDR1 promoter.
Identification of a promoter cis-acting element responsible for benomyl-dependent MDR1 upregulation Systematic 59 deletions of the MDR1 promoter were performed in order to identify the cis-acting regulatory elements involved in the response to benomyl. The MDR1-lacZ promoter constructs were introduced into strain DSY449 at the MDR1 genomic locus by double recombination as described in Methods (see also Fig. 1a) . Correct integration was verified by Southern blot analysis (Fig. 1b) .
A single transformant containing each deletion construct was chosen for testing of reporter activity in the absence and presence of benomyl. As shown in Fig. 2(a) , the reporter under control of the proximal 1459 bp of the MDR1 promoter exhibited a 26?1±4?4-fold increase of activity upon exposure to benomyl. Progressive deletions (99 to 141 bp) from 21459 to 2302 (with respect to the ATG start codon) did not significantly alter the relative increase of reporter activity due to benomyl exposure. However, deletion of the region between 2302 and 2201 resulted in a 10-fold decrease in benomyl-dependent reporter activity, indicating that the minimal domain required for dramatic benomyldependent upregulation must lie within this region. This element was named BRE (for benomyl response element). To further delimit the BRE, small deletions of the region between nucleotides 2302 and 2222 were generated (Fig. 2b) . Progressive 4 to 7 bp (2302 to 2279) and 18 to 20 bp deletions (2279 to 2222) revealed that benomyl-dependent MDR1 transcription was significantly lowered by removal of sequence downstream of 2296. The benomyl-dependent increase in reporter activity was 22?9±3?1-fold for the construct containing the MDR1 promoter region terminating at 2296. It decreased to 4?7±0?7-and 6?4±1?1-fold for constructs with promoters terminating at 2290 and 2286, respectively. A further decline of relative reporter activity to 2?1±0?5-fold at 2279 was also observed. These data indicate that the 59 extremity of the BRE lies between 2296 and 2279. A residual twofold increase in benomyl-dependent transcription appears to be independent of the BRE and suggests that the basal MDR1 promoter can still respond to the drug. until the region between 2598 and 2501 was removed. In strains expressing a reporter under the control of the proximal 2598 nucleotides of the MDR1 promoter, the relative increase of reporter activity after H 2 O 2 exposure was 10?0±2?8-fold, while the relative increase in H 2 O 2 -dependent reporter activity dropped to only 1?5±0?15-fold when the MDR1 promoter terminated at 2501 (Fig. 3a) . Progressive 18 to 21 bp deletions of the promoter region between 2598 and 2520 (Fig. 3b) The cis-acting BRE, but not the HRE, is involved in MDR1 upregulation of an azole-resistant strain
To evaluate the role played by the BRE and HRE in the constitutive high expression of MDR1 that occurs in some azole-resistant strains, promoter deletion constructs were also inserted at the genomic MDR1 locus of the fluconazoleresistant strain FR2, which constitutively expresses MDR1 at high levels (Albertson et al., 1996) . In general, the specific bgalactosidase activities measured in this strain (Fig. 4) with MDR1 promoter lengths between 2999 and 2302 [mean 58?2±5?5 Miller units (U)] were significantly higher than those in strain DSY449 upon its exposure to benomyl (mean 4?7±1?7 U). Moreover, reporter activities were not significantly altered when FR2 cells were exposed to benomyl (data not shown). As shown in Fig. 4(a) , reporter activities were not significantly altered by promoter deletions ranging from 2999 to 2302, thus indicating that the cis-acting HRE located between 2561 and 2520 was not required for constitutive high expression of MDR1 in FR2. In contrast, removal of the promoter sequences between 2302 and 2201 resulted in a more than 10-fold decrease in reporter activity. Interestingly, upon progressive shortening of the MDR1 promoter from 2296 to 2279 (Fig. 4b) , the data indicate a stepwise decrease in reporter activities: a first significant decrease between 2296 (56?1±3?9 U) and 2290 (40?8±4?8 U) and a second significant decrease between 2286 (36?7±2?1 U) and 2279 (2?6±0?2 U). This stepwise decline in reporter activities is reminiscent of that observed for the same promoter deletions in strain DSY449 exposed to benomyl (Fig. 2b) , suggesting that both benomyl-induced transcription and constitutive high expression of MDR1 may be under control of the same functional subelements within the BRE.
Transversions and deletions within the BRE
Deletions and transversions (G to A, C to T, A to G and T to C) within the region containing the cis-acting BRE identified by promoter deletion analysis (2296 to 2279) were undertaken to verify the involvement of this element both in the benomyl-dependent response and in the constitutively high expression of MDR1 observed in the azoleresistant strain FR2. The results obtained further establish the minimal sequence element required for the expression of MDR1 in both conditions. Transversions within the putative BRE (T1: 2287 to 2266) or of smaller regions within this element (T2: 2295 to 2286; T3: 2282 to 2274; and T4: 2276 to 2267) had a dramatic effect on the response to benomyl in strain DSY449 (Fig. 5a ). For transversions T1 to T3, the residual increase in reporter activity in benomyltreated cells as compared to the full-length promoter (22?1±2?6 fold) was between 1?4±0?02-and 2?0±0?3-fold, similar to that of constructs under control of the basal promoter (Fig. 2, promoter deletions 2201 and 298) . The effect of transversion T4 was also significant but less pronounced. Benomyl treatment still caused a 6?4±2?2-fold increase in the activity of this reporter, suggesting that the BRE retained some functional capacity. Consistent with these results, the deletion of the region containing the BRE (D1: 2291 to 2269, ) also abolished the increase of reporter activity in response to benomyl (Fig. 5b) . The relative increase of reporter activity was 1?3±0?2-fold with internal deletion D1 compared with 29?0±2?7-fold with the fulllength MDR1 promoter. Smaller internal deletions within this region (D2: 2295 to 2287; D3: 2286 to 2278; and D4: 2277 to 2269) also decreased benomyl-induced reporter The full-length MDR1 promoters with transversions T1 to T4 within the BRE were fused to the lacZ reporter gene and constructs were inserted into strain DSY449, which was exposed to benomyl, and into FR2 in single copies as outlined in Fig. 1(a) . activities as compared to the full-length promoter, but did not completely abolish the response. The promoter carrying deletion D2 (2295 to 2287) still showed a 17?1±5?5-fold increase in relative reporter activity in response to benomyl treatment, while the promoters carrying deletions D3 and D4 retained a less pronounced response to benomyl treatment (10?0±2?5-fold and 10?7±1?5-fold increase, respectively). The results confirmed that the BRE delimited by successive 59 promoter deletion analysis (2296 to 2276) is essential for the benomyl-dependent response of MDR1. It is however interesting to note that transversions T2 and T3 had significantly more severe effects on benomyl-dependent transcriptional activity than did the deletions D2 and D3.
The effects of the same transversions and deletions upon constitutively high expression of the MDR1 promoter were investigated in the background of the azole-resistant strain FR2. Transversions T1 to T4 each diminished reporter activities but none of them completely abolished the increase over activity measured in the azole-susceptible strain. Relative to the unaltered MDR1 promoter, the constitutive activities of MDR1 promoters carrying transversions T1, T2, T3 and T4 were respectively 3?7-, 2-, 11?6-and 8?7-fold lower (Fig. 5a ). The constitutive activities of MDR1 promoters bearing internal deletions D1, D2, D3 and D4 were respectively 3?5-, 1?7-, 1?7-and 2?5-fold lower than for the MDR1 promoter that had no internal deletion (Fig. 5b) . As previously noted for benomyl-dependent reporter activity, partial transversions of the BRE tended to have more severe effects than the corresponding deletions. However in this case, it was transversions T3 and T4 that had significantly stronger effects than deletions D3 and D4. These results demonstrate that the region containing the BRE also plays a role in the high constitutive expression of MDR1.
The partial retention of reporter activity in constructs lacking parts of the BRE may suggest that this regulatory region is composed of several discrete functional domains but we cannot rule out the involvement of other compensatory mechanisms. Moreover, while 59 deletions only delimit the 59 extremity of regulatory elements (i.e. 2296, see Fig. 2b ), the results presented above aid the localization of central elements of the BRE. Deletions D2 (2295 to 2287), D3 (2286 to 2278) and D4 (2277 to 2269) all led to a decrease of benomyl-dependent MDR1 response and of reporter activity in strain FR2, thus indicating that they all contain nucleotides important for the functionality of the BRE. Since these three deleted regions are sequential in the MDR1 promoter, it can be concluded that at least all the nucleotides of the central deleted region D3 (2286 to 2278) are part of the BRE.
Cap1p, a bZip transcription factor, acts as a trans-acting factor of MDR1 regulation (Fig. 3a, black columns) . Thus, H 2 O 2 -dependent expression is essentially completely lost in the cap1D/D strain irrespective of whether the HRE is present. Therefore Cap1p is likely to be the main positive regulator involved in the response of the MDR1 promoter to H 2 O 2 . We also examined the benomyl-dependent response of reporters under control of MDR1 promoter fragments in the cap1D/D strain. Inactivation of CAP1 did not prevent the different reporter constructs from responding to benomyl. Reporter constructs carrying at least 302 nucleotides of the proximal MDR1 promoter showed a benomyl-dependent increase in activity (13?0±5?1-fold, black columns Fig. 2a ). However, since the level of the responses was generally twofold lower than that recorded in the corresponding wild-type strain (25?9±5?3-fold, white columns Fig. 2a) , we cannot exclude the possibility that Cap1p plays a minor role in mediating the transient response to benomyl. Finally, we observed no significant differences between the specific reporter activities measured in the azole-resistant strain FR2 (58?2±5?5 U) and the corresponding cap1D/D mutant MMY412 (51?3±7?5 U, Fig. 4a ), indicating that Cap1p is not necessary for constitutive high expression of MDR1 in FR2.
Importance of the cis-acting HRE for MDR1 regulation
As the response of MDR1 to benomyl was partially reduced in the strain lacking CAP1, the deletion of a region (2552 to 2521) within the HRE (delimited between 2561 and 2520) was performed in the full-length MDR1 promoter and reporter activities were measured under benomyl exposure in DSY449. As shown in Fig. 6(a) , deletion of the region between 2552 and 2521 within the full-length MDR1 promoter did not alter the response to benomyl: the increase in reporter activity after benomyl exposure (25?7±5?0-fold) was not significantly different from that in the control (30?1±3?1-fold). The simultaneous deletion of the BRE and HRE resulted in a similar effect to the deletion of the BRE alone (2?1±0?5-fold versus 1?3±0?2-fold increase in reporter activity). Consistent with the results shown in Fig. 2(a) , these results indicate that the upregulation of MDR1 under benomyl exposure is not dependent on the HRE. The HRE was also not involved in high constitutive expression of MDR1 in strain FR2. In this strain, reporter activities were identical in the presence (66?4±5?2 U) or absence (73?6±3?7 U) of the HRE (Fig. 6b) . Moreover, reporter activities after the simultaneous deletion of BRE and HRE (23?6±2?6 U) were also similar to those observed in the absence of the BRE (16?3±0?7 U) (Fig. 6b) .
In contrast, the effects of the deletion of the HRE and BRE suggested that both elements were involved in H 2 O 2 -dependent response of MDR1. Under H 2 O 2 exposure (Fig. 6c) , the increase in reporter activity measured with the promoter lacking the BRE (5?6±1?0-fold) was approximately twofold lower than that with the full-length promoter (9?4±2?0-fold). In the absence of HRE, as well as with the simultaneous deletion of HRE and BRE, the relative increase of reporter activity in response to H 2 O 2 exposure was 2?9±0?1-fold and 2?0±0?7-fold, respectively, which represents a threefold and 4?6-fold lower response than that recorded for reporters under control of the fulllength promoter. This suggests that not only the HRE but also the BRE could mediate H 2 O 2 -dependent responses of MDR1.
In summary, our results show that the HRE is not essential for MDR1 upregulation by benomyl or in an azole-resistant isolate but is required for H 2 O 2 -dependent regulation of this gene. In the presence of H 2 O 2 , Cap1p is likely to act in trans on the MDR1 promoter through the HRE. While we cannot exclude an indirect role for Cap1p in the benomyl response, it does not act through either of the cis-acting elements that we have identified in MDR1.
The BRE and HRE are functional in a heterologous promoter
To further assess the cis-acting role of the BRE in response to benomyl, the element was placed in a minimal 198 bp CDR2 promoter lacking its own regulatory element (DRE). The CDR2 promoter is not responsive to benomyl and is therefore convenient for addressing the involvement of the BRE in this process. A BRE-CDR2 chimeric promoter was constructed and used with a Renilla luciferase reporter system. Because the sequences immediately flanking the BRE may modulate its function, a 50 bp MDR1 promoter sequence was used which spanned nucleotides 2309 to 2260. The reporter system was inserted at the LEU2 genomic locus of strains DSY449 and FR2. As shown in Fig. 7(a) , the presence of the BRE conferred benomyl responsiveness to the minimal CDR2 promoter. Up to 12?0±2?1-fold increase in reporter activity could be measured in benomyl-treated cells as compared to the control, untreated cells. Activity was reduced however as compared to the native 592 bp MDR1 promoter (72?8±5?6-fold). When two copies of the BRE were fused to the CDR2 promoter, the increase in reporter activity (96?8±46?4-fold) was comparable to that of the MDR1 promoter. To assess the role of the HRE in the benomyldependent response, a 41 bp MDR1 promoter sequence spanning nucleotides 2556 to 2516, and containing the HRE with Cap1p-binding sites, was placed upstream of the BRE-CDR2 promoter. The increase in reporter activity induced by benomyl (17?6±1?6-fold) was not significantly different from that observed with the BRE-CDR2 promoter (12±2?1-fold). When the HRE alone was fused to the CDR2 promoter, almost no increase in reporter activity could be detected (1?6±0?5-fold), indicating that the HRE is not involved in the benomyl response of MDR1. In FR2, the BRE-CDR2 chimeric promoter mediated high reporter activity. As shown in Fig. 7(b) , the specific luciferase activity obtained with the BRE-CDR2 fusion (1?9±0?45610 6 RLU) was only 2?5-fold lower than that obtained with the MDR1 promoter (4?9±1?0610 6 RLU). Insertion of two copies of the BRE upstream of the minimal CDR2 promoter gave reporter activities (5?8±1?6610 6 RLU) similar to those measured with the MDR1 promoter. Since the specific reporter activities measured with the HRE-BRE-CDR2 and the BRE-CDR2 fusions (1?7±0?3610 6 and Fig. 6 . Effects of HRE deletions on MDR1 regulation. Nucleotide deletions within the HRE were generated in the full-length promoter or in the BRE-deleted MDR1 promoter. Nucleotide coordinates are given for each deletion. Each HRE deletion was analysed either in DSY449 exposed to benomyl (a) or to 
1?9±0?5610
6 RLU, respectively) were similar and only background reporter activity was detected with the HRE alone (<10 4 RLU), the HRE was not considered to be involved in the high levels of expression of MDR1 in FR2. The data presented in Fig. 7 also contribute to a more precise localization of the functional BRE. Placing the 59extremity at position 2296 as previously determined, the 39 extremity can be proposed to be at position 2260, since this corresponds to the position identified in the testing of BRE functionality.
We investigated whether the HRE could confer an H 2 O 2 -dependent response to the minimal CDR2 promoter in strain DSY449 (Fig. 7c) . However, when the HRE alone was fused to the minimal CDR2 promoter, the relative increase in reporter activity (1?9±0?7-fold) was not different from the background activity increase measured with the basal CDR2 promoter (2?0±1?0-fold). The relative increase in reporter activities after H 2 O 2 exposure obtained with the BRE-CDR2 promoter was similar (2?9±1?8-fold) to that with the HRE-CDR2 promoter. However, when the HRE was placed upstream of the BRE-CDR2 promoter, a 43?0±3?1-fold increase in reporter activity generated by H 2 O 2 exposure was measured, which was 1?6-fold higher than with the MDR1 promoter (27?3±3?7-fold). Thus, consistent with our observation that deletion of either element reduced the H 2 O 2 -dependent response of the MDR1 promoter, both elements are required to convey significant H 2 O 2 -dependent upregulation to a heterologous promoter.
Trans-acting factors bind to the BRE
To assess the possible interaction between the BRE and putative transcription factors present in C. albicans protein extracts, EMSAs were performed with double-stranded probes corresponding to several regions of the BRE. In this experiment, it was possible to observe the formation of a DNA-protein complex with labelled probe 1 (2296 to 2259; Fig. 8a ), which contained the BRE delimited by 59 promoter deletion analysis and insertion into another promoter context (between 2296 and 2260). This complex was present at higher levels, as revealed by the intensity of the band, when a protein extract from benomyl-exposed cells was used in comparison to that observed with proteins from untreated cells. The protein-DNA complex was specific for the BRE, since competition with increasing amounts of unlabelled BRE resulted in the disappearance of the complex (Fig. 8a) . Furthermore, in the presence of a molar excess of an unlabelled probe, corresponding to a promoter region of the RTA4 gene, the formation of the protein-DNA complex could be still observed. Finally, using this labelled RTA4 as a probe (probe 2), formation of a protein-DNA complex with a similar migration pattern was not observed.
Labelled probes harbouring transversions identical to those used in promoter analysis (T1 to T4: probes 3-6) were also incubated with C. albicans protein extracts. However, as illustrated in Fig. 8(b) , no specific band could be detected, thus corroborating the negative effects of these transversions upon reporter activities. Moreover, EMSAs carried out with labelled probes harbouring internal deletions (deletion D5: probe 7, 2282 to 2277 and deletion D6: probe 8, 2285 to 2274) showed no specific binding (Fig. 8b) . This result is consistent with the finding that deletions within this region strongly reduced reporter activities (Fig. 5b) . These results Fig. 7 . Insertion of the BRE and HRE into the CDR2 promoter. BRE-(black rectangle) and HRE-(grey rectangle) containing sequences were first cloned upstream of the first 198 bp of the promoter of CDR2 fused to the Renilla luciferase reporter gene. This minimal promoter is lacking the DRE but still contains elements required for efficient transcription. The effects of addition of HRE and/or BRE to the CDR2 promoter were analysed either in DSY449 exposed to benomyl (a) or to H 2 O 2 (c), or in FR2 (b). The results are given as relative increase of reporter activity after benomyl or H 2 O 2 exposure in strain DSY449 or as specific activities for reporter expression, expressed in RLU, in strain FR2. The values are the means of single measurements obtained with three independent clones. Asterisks indicate the position of values that differ significantly (P¡0?05) from those obtained with the minimal CDR2 promoter in Mann-Whitney tests.
show that the promoter regulatory region previously delimited (2296 to 2260) corresponds to that which can bind sequence specific protein complexes in vitro.
To further delimit the BRE sequence necessary for the binding in trans of specific protein complexes, band-shift assays were performed with probe lengths reduced at both the 59 and 39 extremities of probe 1 (2296 to 2259) containing the BRE. Removal of 5 and 6 bp at the 59 extremity of probe 1 (respectively probes 9 and 10) and of 5 to 13 bp at its 39 extremity (probes 15-17) did not abolish the formation of a DNA-protein complex (Fig. 9a) . The intensity of bands for protein complexes with probes lacking 7 bp at the 59 extremity (probe 11) or 14 bp at the 39 extremity (probe 18) was slightly reduced as compared to the full-length probe 1. Finally, removal of at least 8 bp at the 59 extremity (probes 12-14) or at least 15 bp at the 39 extremity (probes 19-22) resulted in the absence of protein complex formation (Fig. 9a) . The results show that the minimal protein-binding region of the BRE is likely to be from 2290 to 2273. As expected, a specific DNA protein complex could be revealed (Fig. 9b) by using a labelled probe covering this region (probe 23).
DISCUSSION

Cis-acting regulatory elements of the MDR1 promoter
In this study, we report the identification of two cis-acting promoter elements, the HRE and the BRE, important for the regulation of MDR1. The first element, the HRE, was localized to between 2561 and 2520 by promoter deletion Fig. 8 . Specific protein complexes are formed with the BRE. (a) EMSA of the BRE with protein extracts from CAF2-1 cells exposed or not exposed to benomyl. Labelled probes 1 and 2 correspond to the sequence of the BRE ("296 to "259), which is longer than the BRE-containing domain delimited by promoter deletion analysis, and to the promoter sequence of RTA4 ("165 to "123), respectively. Labelled probes were separated as described in Methods. Arrows indicate the position of specific and non-specific DNA-protein complexes and of free probes. Specificity of binding was assayed by competition with varying amounts of unlabelled probes 1 and 2. (b) EMSA of the BRE with transversed or deleted oligonucleotide probes. Cell extracts were obtained from CAF2-1 exposed to benomyl. The sequences of probes are shown at the bottom. Transversions are underlined whereas deleted nucleotides are outlined in grey. The BRE probe (probe 1) served as a positive control for DNA-protein complex formation. analysis and was responsible for H 2 O 2 -dependent MDR1 regulation. A transcriptional response of the MDR1 promoter to the oxidizing agent T-BHP, previously delimited by Harry et al. (2005) to lie within the region (2601 to 2500), might also be attributable to the HRE. The HRE contains two YRE-like sequences, one that perfectly matches the consensus sequence (2532 to 2526: TTAGTAA) and a second that differs from the consensus by two nucleotides (2549 to 2543: TAACTAT). Deletion of the HRE almost abolished the H 2 O 2 -dependent response of the MDR1 promoter (Fig. 3) , suggesting strongly that the YRE-like sequences play a central role in this induction. The HRE within the MDR1 promoter may be a downstream target of Cap1p, the functional homologue of the S. cerevisiae Yap1p, a bZip transcription factor binding to the YRE consensus sequence (Zhang et al., 2000) . In accordance with this hypothesis, the deletion of CAP1 abolished the H 2 O 2 response of MDR1. However, the absence of the HRE did not alter the response of the MDR1 promoter when C. albicans was exposed to benomyl. In contrast, the promoter of FLR1 from S. cerevisiae (a functional homologue of MDR1) was shown to be activated by benomyl via a YRE (Nguyen et al., 2001) . Such speciesspecific differences serve to illustrate that the signal transduction pathways regulated by CAP1 and YAP1 are likely to have evolved significant differences despite the evidence for functional conservation of some of their downstream targets. Surprisingly, the HRE had no impact on high constitutive expression of MDR1, since absence of this element did not alter MDR1 expression (Fig. 6) . Moreover, when fused to the promoter CDR2, the HRE was unable to confer a high reporter activity in FR2. In the background of an FR2-derived mutant lacking CAP1, MDR1-lacZ reporter activities were also unchanged as compared to the parent strain. These ("290 and "273) and proteins from CAF2-1 cells exposed or not exposed to benomyl. The sequence of the probe used is given at the bottom. A sequence from the RTA4 promoter was used as a non-specific competitor (see Fig. 8 ).
results highlight the existence of distinct transcriptional programmes responsible for MDR1 upregulation. While the influence of the HRE appears restricted to the H 2 O 2 response, the deletion of CAP1 also decreased, but did not eliminate, the benomyl-dependent response of MDR1 (Fig. 2) . Thus, our work reveals that there is some degree of crosstalk between the elements that mediate distinct responses. As the benomyl response of MDR1 is dependent on the BRE, we speculate that Cap1p may cooperate with unknown factor(s) acting on the BRE.
The second cis-acting element of the MDR1 promoter, the BRE, was responsible both for the benomyl-dependent response of MDR1 and for high constitutive expression of this gene in the azole-resistant strain FR2. The delimitation of the minimal regulatory element that constitutes the BRE requires still further promoter analysis. The promoter truncations we examined have only delimited the 59 extremity of the regulatory elements (i.e., 2296, see Fig. 2 ); internal deletions and transversions (Fig. 5) demonstrated that nucleotides between 2286 and 2278 are part of the BRE, but do not give a precise position of the 39 extremity of the regulatory element. Nevertheless, the 39 functional extremity of the BRE can be deduced from results obtained with the BRE-CDR2 promoter fusion. They suggest that the position of the 39 extremity must lie upstream of position 2260, therefore defining the functional BRE between 2296 and 2260. In the light of results obtained by EMSA with oligonucleotides corresponding to the sequence of the BRE, the minimal oligonucleotide length still enabling sequence-protein binding was determined to be located between 2290 and 2273 (Figs. 8 and 9 ) and thus lies fully within the functionally defined BRE. The convergence of both methods to this specific region of the promoter strengthens its implication as a regulatory element. In vivo and in vitro footprinting analysis of the BRE can now be applied to aid precise delimitation of this regulatory element and the further characterization of the proteins that bind to it.
The functional cis-acting BRE identified in our work (2296 to 2260) lies close to a cis-acting benomyl-responsive region, as delimited by a separate study (Harry et al., 2005) . In that study, removal of the region between 2399 and 2299 led to a 20-fold diminution of the benomyldependent increase in reporter gene activities, whereas a weaker diminution (two-to fourfold) was observed when the region between 2299 and 2200 was absent from the MDR1 promoter. Thus, while both studies indicate that the BRE-containing sequences are important, we have not seen evidence of a second, more distal benomyl-responsive element. This discrepancy could be the result of several factors, including the strain background or the type of gene reporter system used to assess promoter activity. Above all, the genomic site of reporter gene insertion might contribute to such differences. In the present study, the MDR1-lacZ reporter system was integrated at the MDR1 genomic locus, whereas the Renilla luciferase reporter system used in the study of Harry et al. (2005) was inserted at the ADE2 genomic locus. A very recent study by Hiller et al. (2006) also shows the existence of several cis-acting domains in the MDR1 promoter. This promoter analysis was performed with a GFP reporter system integrated at the ACT1 locus in an azole-susceptible strain exposed to benomyl (3 h at 50 mg ml
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) and in an azole-resistant isolate expressing MDR1 at high levels. This experimental context is similar to the one used here, except that the drug exposure time was longer and the gene reporter system was different and not integrated at the MDR1 locus. The authors identified three different regulatory regions (region 1: 2397 to 2301; region 2: 2588 to 2500; region 3: 2287 to 2209). In their study, region 2 was implicated in the benomyl-dependent MDR1 response and regions 1 and 3 were required for constitutive high expression of MDR1. Thus while there is some consensus of agreement on the delimitation of regulatory regions, there are also significant discrepancies between the findings of Hiller et al. (2006) and the other two studies, this work and Harry et al. (2005) . Most notably, our results clearly implicate the HRE in the H 2 O 2 response of MDR1, while Hiller et al. (2006) found that the region encompassing this element (region 2) was responsible for benomyldependent MDR1 upregulation, a feature not confirmed in our study. The discrepancies between these different studies could have several origins, as mentioned above. The details of which regulatory elements respond to particular signals may also depend on chromatin-mediated factors and the gene's global context within the genome. Thus we believe it is of importance to have integrated the reporter constructs at the MDR1 locus. Moreover, the demonstration that we can recapitulate the functions of the HRE and BRE in the context of another promoter further validates the transcriptional cis-acting roles that we assign to them. Furthermore, we demonstrated protein binding to the BRE, thus confirming that this cis-acting element may interact with as yet unknown factor(s).
A BRE-like sequence is present in the promoter of genes co-regulated with MDR1 and contains a Mcm1p-binding site
In a previous study, we determined, by transcript profiling experiments, that MDR1 was co-regulated with other genes in an azole-resistant strain and in a susceptible strain exposed to benomyl (Karababa et al., 2004) . We therefore expected to identify a common regulatory cis-acting motif resembling the BRE in the promoters of these genes. Alignment of promoter sequences revealed that nine of the 16 commonly upregulated genes indeed contain one or two sequences that match the signature of the BRE (Fig. 10a) . Conserved sequence 1 (2287 to 2267) in the MDR1 promoter matches the previously delimited BRE (2296 to 2260) and differs by 4 nucleotides from the consensus established after promoter sequences alignment (59-TCCMMWTTWGKAAAKTYHCCG-39). While the presence of the BRE signature in these promoters is therefore consistent with their co-regulation, additional work will be required to confirm that the BRE is important for the regulation of these genes. A second BRE-like sequence (2496 to 2476) was identified in the MDR1 promoter (see Fig. 10a) ; however, promoter deletion analysis revealed that this sequence is not involved in MDR1 regulation either in DSY449 exposed to benomyl or in FR2. Furthermore, EMSA with a probe corresponding to this second sequence failed to reveal protein-binding activity (data not shown).
When inspecting the BRE sequence (2296 to 2260) for known transcription factor binding sites, using the TESS Master software (http://www.cbil.upenn.edu/cgi-bin/tess/ tess?RQ), a binding site for Mcm1p (CCTAATTGGG; 2288 to 2277) matching the consensus binding site (CCYWWWWNGN) (Chang et al., 2003; Passmore et al., 1989; Spellman et al., 1998; Wynne & Treisman, 1992 ) was localized within this sequence. A similar promoter context exists in the MDR1 promoter of Candida dubliniensis (Fig. 10b) , a species related to C. albicans in which MDR1 upregulation has been demonstrated (Moran et al., 1998) . The presence of the putative Mcm1p-binding site in the BRE suggests that Mcm1p could act as a trans-acting factor on the BRE and thus be involved in the regulation of MDR1 via the BRE. Interestingly, this sequence overlaps the region deleted in Fig. 5 (D3: 2286 to 2278), which was considered to be a central part of the BRE. In S. cerevisiae, MCM1 is an essential gene of the MADS box transcription factor family involved in a variety of cellular processes, including chromatin remodelling, arginine response and mating as well as cell cycle regulation (Keleher et al., 1988; Passmore et al., 1988) . In C. albicans, MCM1 is crucial for the determination of cell morphology and is autoregulated by a feedback mechanism. Fig. 10 . BRE-like consensus in genes from Candida species. (a) Identification of a potential consensus regulatory sequence in the promoters of genes co-regulated with MDR1 under benomyl-exposed conditions and in an azole-resistant strain. The co-regulated genes were described previously (Karababa et al., 2004) . Alignment of promoter sequences (815 to 1000 bp) was performed with the software MEME, available at http://meme.sdsc.edu/meme/meme.html, with the following parameters: number of motifs, 5; minimum number of sites, 2; maximum number of sites, 50; minimum width of motif, 6; maximum width of motif, 30. The number of copies of the consensus sequence present within the same promoter is indicated in parentheses. IFD1 and IFD5 correspond to two alleles of the same gene. Only nucleotides with probabilities of 0?2 or higher at that position in the motif appear in the consensus. The P value represents the probability of a random string (generated from the background nucleotide frequencies) having the same match score or higher within the promoter. Nucleotide symbols are as follows: M=A/C, W=A/T, Y=T/C, K=A/T, H=T/C/A. (b) Alignment of MDR1 promoter sequences from C. albicans and C. dubliniensis. Bases matching the Mcm1p-binding site are indicated in bold. Nucleotide sequences were obtained from the Pasteur database at http://genolist.pasteur.fr/CandidaDB/index.html and from the C. dubliniensis database at http:// www.sanger.ac.uk/sequencing/Candida/dubliniensis/.
Depletion of Mcm1p leads to constitutive induction of hyphae. However, overexpression under specific conditions also results in enhanced hyphae formation. It has been hypothesized that Mcm1p might act as a mediator recruiting regulatory factors required for morphogenesis (Rottmann et al., 2003) . MCM1 is essential in C. albicans (Rottmann et al., 2003) , and thus experimental approaches to validate its involvement in MDR1 regulation are difficult. Chromatin immunoprecipitation (ChIP) experiments and EMSA with a labelled BRE probe using tagged Mcm1p are currently being undertaken in our laboratory and should address whether Mcm1p is effectively a trans-acting factor involved in the regulation of MDR1 through the BRE.
In summary, the work presented here has enabled the precise delimitation of two cis-acting regulatory elements (HRE and BRE) in the MDR1 promoter. We have shown that Cap1p is likely to be one trans-acting factor for the HRE; however, confirmation of its role and the full identification of the trans-acting components with which it interacts will necessitate further investigation. Future studies will also clarify whether mutations in MCM1 can be responsible for high constitutive expression of MDR1 in a manner analogous to the recent finding that mutations in TAC1, a key trans-acting regulator of the ABC-transporter genes CDR1 and CDR2, are responsible for the high CDR1/ CDR2 expression of clinical strains (Coste et al., 2006) .
NOTE ADDED IN PROOF
While this paper was in press, a separate study from P. Riggle from the group of C. Kumamoto (Tufts University School of Medicine, Boston) was published (Eukaryotic Cell, in press: doi:10.1128/EC.00243-06) that identified a cis-acting regulatory element of MDR1 identical to the BRE delimited in this work and that showed the binding of Mcm1p to this element.
